Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of PEX010 in combination with cognitive-behavioural therapy (CBT) for patients with depression

Next Previous
Trial Profile

Clinical study of PEX010 in combination with cognitive-behavioural therapy (CBT) for patients with depression

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Psilocybin (Primary)
  • Indications Depression
  • Focus Therapeutic Use

Most Recent Events

  • 11 Aug 2023 New trial record
  • 08 Aug 2023 According to a Filament Health media release, this trial will led by Dr. Marc Weintraub,
  • 08 Aug 2023 According to a Filament Health media release, the company received approval from the United States Food and Drug Administration (FDA) for this trial. This trial is being conducted at the University of California, Los Angeles (UCLA)'s Semel Institute for Neuroscience and Human Behavior.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top